Published in J Clin Oncol on February 16, 2010
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol (2012) 0.88
Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma. Adv Hematol (2010) 0.82
Polymeric micelles for multi-drug delivery in cancer. AAPS PharmSciTech (2014) 0.78
Early-stage favorable Hodgkin's lymphoma: is chemotherapy alone sufficient? J Clin Oncol (2010) 0.75
The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years? Biomed Res Int (2015) 0.75
Hematology in 2010: New therapies and standard of care in oncology. Nat Rev Clin Oncol (2011) 0.75
Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data? J Clin Oncol (2010) 0.75
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma (2014) 2.40
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med (2012) 2.22
Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park) (2010) 2.09
Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer (2013) 1.98
Case of the Massachusetts General Hospital: Case 35-2013: a 77-year-old man with confusion and malaise. N Engl J Med (2013) 1.98
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2004) 1.91
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol (2010) 1.88
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol (2013) 1.67
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2011) 1.62
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood (2005) 1.59
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol (2009) 1.57
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Primary subcutaneous Alternaria alternata infection of the hand in an immunocompromised host. Med Mycol (2011) 1.47
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
Evaluating the impact of the humanities in medical education. Mt Sinai J Med (2009) 1.39
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2006) 1.34
Diagnosis and management of Castleman disease. Cancer Control (2014) 1.32
Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw (2013) 1.20
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood (2012) 1.15
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res (2013) 1.15
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res (2006) 1.11
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma (2009) 1.10
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol (2008) 1.09
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol (2002) 1.09
Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant (2007) 1.07
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2011) 1.06
Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist (2009) 1.06
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer (2010) 1.05
Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw (2012) 1.03
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov (2011) 1.02
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol (2012) 1.00
Enzastaurin. Expert Opin Investig Drugs (2008) 1.00
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer (2011) 0.97
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer (2003) 0.97
Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol (2007) 0.94
Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw (2014) 0.94
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2002) 0.93
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis (2013) 0.92
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer (2013) 0.90
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma (2013) 0.89
Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw (2016) 0.89
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol (2012) 0.88
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma. J Clin Oncol (2004) 0.85
Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery. J Clin Oncol (2011) 0.84
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res (2004) 0.83
Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2002) 0.83
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica (2012) 0.83
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys (2011) 0.83
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer (2014) 0.82
Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol (2012) 0.82
Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol (2009) 0.82
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol (2013) 0.81
Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol (2009) 0.81
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol (2013) 0.81
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw (2015) 0.81
Kaposi's Sarcoma-Associated Herpesvirus-Related Solid Lymphoma Involving the Heart and Brain. AIDS Res Treat (2011) 0.79
Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys (2005) 0.79
Biology of double-hit B-cell lymphomas. Curr Opin Hematol (2012) 0.79
Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol (2011) 0.79
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.79
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer (2014) 0.78
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma (2013) 0.78
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology (2013) 0.78